Could a Lower-Dose polio vaccine help eradicate the disease?
NCT ID NCT06413121
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 healthy infants aged 6-8 weeks will receive three primary doses and a booster. If effective, this approach could lower costs and increase vaccine supply, aiding global polio eradication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hexavalent (DTwP-HepB-IPV-Hib) vaccine with reduced dose IPV
What this could lead to
If successful, this vaccine could help make polio protection more affordable and available worldwide, supporting global eradication efforts.
What could go wrong
This is a phase 3 trial, but reducing the IPV dose might still result in lower immune responses for some infants. Safety and effectiveness need confirmation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIPTHERIA IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bharati Vidyapeeth Medical College and Hospital, Pune
Pune, Maharashtra, 411043, India
-
Hamdard Institute of Medical Sciences and Research (HIMSR) with Centre for health research & Development, Society for applied studies, Hakeem Abdul Hameed Centenary Hospital (HAHCH)
New Delhi, National Capital Territory of Delhi, 110062, India
-
Institute of Child Health, Kolkata
Kolkata, West Bengal, 700017, India
-
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Kamalapur Field office, Lichubagan Rd
Dhaka, Dhaka Division, 1204, Bangladesh
-
International Centre for Diarrhoeal Disease Research, Bangladesh (Icddr,b), Clinical Trial Unit (CTU), Adjacent to the main center, 68, Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka
Dhaka, Dhaka Division, 1212, Bangladesh
-
International Centre for Diarrhoeal Disease Research, Bangladesh (Icddr,b), Matlab Field office, MHRC Internal Road, Matlab Bazar
Chāndpur, 3640, Bangladesh
-
JSS Medical College and Hospital
Mysore, Karnataka, 570004, India
-
KEM Hospital and Research Centre, Vadu
Pune, Maharashtra, 412216, India
-
Manipal Academy of Higher Education, Manipal
Mangalore, Karnataka, 576104, India
-
Post Graduate Institute of Medical Education and Research (PGIMER)
Chandigarh, Chandigarh, 160012, India
-
Sri Ramachandra Medical Centre, Chennai
Chennai, Tamil Nadu, 600116, India